Abstract
Posttherapy positron emission tomography/computed tomography (PET/CT) scanning in patients with malignant lymphoma remains controversial. We aimed to evaluate the utility of achieving histologic verification of positive PET/CT findings in the follow-up of patients with malignant lymphoma. A total of 771 PET/CT scans were performed as posttherapy follow-up in 190 lymphoma patients who had experienced a complete remission at our institution. Fifty-two patients (27.3%) had (18)F-fludeoxyglucose-positive lesions on posttherapy PET/CT, and a histologic diagnosis was carried out in 32 cases (16.8%). Ten patients (5.2%) exhibited relapse of lymphoma. Twelve lesions in 11 patients (5.8%) were proven to be second primary malignancies (SPM). Eleven patients (5.8%) were proven to have benign or normal tissue lesions. Among the 32 histologically verified PET/CT-positive patients, the symptomatic PET/CT-positive patients (n = 10; 4 SPM, 6 lymphoma relapse) had a significantly shorter overall survival rate than the asymptomatic PET/CT-positive patients (n = 22; 7 SPM, 4 lymphoma relapse, 11 benign/normal tissue lesions) (2-year overall survival, 48.2% vs. 100%, respectively; P < .001). This study emphasizes that the histologic diagnosis shou...Continue Reading
References
Feb 1, 1997·BMJ : British Medical Journal·J A RadfordD Crowther
Dec 31, 2003·Radiology·Harry Agress, Benjamin Z Cooper
Apr 30, 2005·Blood·Corinne HaiounMichel Meignan
May 5, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M LiedtkeA D Zelenetz
Nov 30, 2006·Cancer·Guohui WangRodney J Hicks
Mar 16, 2007·Blood·James O Armitage
Nov 30, 2007·The New England Journal of Medicine·David J Brenner, Eric J Hall
Aug 14, 2008·Haematologica·Stefano SacchiMassimo Federico
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniMichele Baccarani
Apr 1, 2009·Radiology·Aaron SodicksonRamin Khorasani
Feb 9, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U PetrauschN G Schäefer
Aug 14, 2010·Annals of Hematology·Neta GoldschmidtOra Paltiel
Oct 27, 2010·International Journal of Hematology·Kazuya SatoKeiya Ozawa
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson
Dec 31, 2011·Haematologica·Tarec Christoffer El-GalalyMartin Hutchings
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H TillyUNKNOWN ESMO Guidelines Working Group
Feb 21, 2013·American Journal of Hematology·Irit AviviRachel Bar-Shalom
Oct 15, 2013·Clinical Lymphoma, Myeloma & Leukemia·Quoc TruongMehdi Hamadani
Dec 19, 2013·Annals of Nuclear Medicine·Ryogo MinamimotoTomio Inoue
Feb 5, 2014·American Journal of Hematology·T C El-GalalyMartin Hutchings
Apr 9, 2014·Cancer·Sai Ravi PingaliTimothy S Fenske
Oct 1, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carrie A ThompsonBrian K Link
Citations
Jun 1, 2016·Annals of Hematology·Hugo J A Adams, Thomas C Kwee
Nov 4, 2016·Annals of Hematology·Hugo J A Adams, Thomas C Kwee
Oct 27, 2016·European Journal of Nuclear Medicine and Molecular Imaging·Hugo J A Adams, Thomas C Kwee
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugo J A Adams, Thomas C Kwee
Dec 29, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugo J A Adams, Thomas C Kwee
Jul 18, 2017·Acta Oncologica·Hugo J A Adams, Thomas C Kwee
Dec 29, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugo J A Adams, Thomas C Kwee
Mar 11, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Hugo J A Adams, Thomas C Kwee